AbbVie Inc.
ABBV
$172.99
$1.310.76%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 56.33B | 55.53B | 55.00B | 54.40B | 54.32B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.33B | 55.53B | 55.00B | 54.40B | 54.32B |
| Cost of Revenue | 16.82B | 16.61B | 16.76B | 16.77B | 16.73B |
| Gross Profit | 39.51B | 38.93B | 38.24B | 37.63B | 37.59B |
| SG&A Expenses | 13.19B | 13.87B | 13.13B | 12.97B | 12.90B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -7.00M | 169.00M | 169.00M | 0.00 | -10.00M |
| Total Operating Expenses | 38.13B | 38.40B | 37.47B | 36.93B | 36.66B |
| Operating Income | 18.20B | 17.14B | 17.53B | 17.47B | 17.66B |
| Income Before Tax | 3.72B | 7.20B | 7.07B | 7.53B | 6.25B |
| Income Tax Expenses | -570.00M | 2.06B | 1.72B | 1.53B | 1.38B |
| Earnings from Continuing Operations | 4.29K | 5.13K | 5.35K | 6.00K | 4.87K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.00M | -11.00M | -11.00M | -11.00M | -10.00M |
| Net Income | 4.28B | 5.12B | 5.34B | 5.99B | 4.86B |
| EBIT | 18.20B | 17.14B | 17.53B | 17.47B | 17.66B |
| EBITDA | 26.59B | 25.50B | 26.04B | 26.12B | 26.36B |
| EPS Basic | 2.40 | 2.87 | 3.00 | 3.37 | 2.73 |
| Normalized Basic EPS | 5.78 | 5.47 | 5.62 | 5.62 | 5.67 |
| EPS Diluted | 2.40 | 2.87 | 3.00 | 3.37 | 2.73 |
| Normalized Diluted EPS | 5.77 | 5.46 | 5.61 | 5.61 | 5.66 |
| Average Basic Shares Outstanding | 7.08B | 7.08B | 7.08B | 7.08B | 7.08B |
| Average Diluted Shares Outstanding | 7.09B | 7.09B | 7.09B | 7.09B | 7.09B |
| Dividend Per Share | 6.29 | 6.20 | 6.13 | 6.06 | 5.99 |
| Payout Ratio | 257.71% | 212.79% | 201.82% | 177.71% | 216.72% |